Eledon Pharmaceuticals to Host R&D Day on July 9, 2025 in New York City
Eledon Pharmaceuticals (NASDAQ:ELDN) announced it will host an R&D Day on July 9, 2025 in New York City, starting at 8:30 am ET. The event will showcase the company's lead investigational candidate, tegoprubart, focusing on its clinical development in organ and cell transplantation, including the ongoing Phase 2 BESTOW trial.
The R&D Day will feature presentations from Eledon's executive team and leading transplantation experts from prestigious institutions. Topics will cover unmet needs in solid organ transplantation, clinical endpoint evolution, and strategic opportunities in islet cell transplantation and xenotransplantation. The event will conclude with a Q&A session and will be available via live webcast.
Eledon Pharmaceuticals (NASDAQ:ELDN) ha annunciato che terr脿 un R&D Day il 9 luglio 2025 a New York, con inizio alle 8:30 ET. L'evento presenter脿 il candidato principale dell'azienda, tegoprubart, concentrandosi sul suo sviluppo clinico nel trapianto di organi e cellule, incluso il trial di Fase 2 BESTOW attualmente in corso.
Durante l'R&D Day, il team esecutivo di Eledon e rinomati esperti di trapianto provenienti da istituzioni prestigiose terranno presentazioni. Gli argomenti tratteranno le necessit脿 non soddisfatte nel trapianto di organi solidi, l'evoluzione degli endpoint clinici e le opportunit脿 strategiche nel trapianto di cellule insulari e nella xenotrapianto. L'evento si concluder脿 con una sessione di domande e risposte e sar脿 trasmesso in diretta via webcast.
Eledon Pharmaceuticals (NASDAQ:ELDN) anunci贸 que realizar谩 un D铆a de I+D el 9 de julio de 2025 en la ciudad de Nueva York, comenzando a las 8:30 am ET. El evento mostrar谩 el candidato principal de la compa帽铆a, tegoprubart, centrado en su desarrollo cl铆nico en trasplantes de 贸rganos y c茅lulas, incluyendo el ensayo de Fase 2 BESTOW en curso.
El D铆a de I+D contar谩 con presentaciones del equipo ejecutivo de Eledon y de destacados expertos en trasplantes de instituciones prestigiosas. Los temas abordar谩n las necesidades no cubiertas en el trasplante de 贸rganos s贸lidos, la evoluci贸n de los endpoints cl铆nicos y las oportunidades estrat茅gicas en el trasplante de c茅lulas de islotes y xenotrasplantes. El evento concluir谩 con una sesi贸n de preguntas y respuestas y estar谩 disponible v铆a webcast en vivo.
Eledon Pharmaceuticals (NASDAQ:ELDN)电� 2025雲� 7鞗� 9鞚� 鞓れ爠 8鞁� 30攵�(霃欕秬鞁滉皠)攵�韯� 雺挫殨鞁滌棎靹� 鞐瓣惮臧滊皽(R&D) 雿办澊毳� 臧滌禍頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. 鞚措矆 頄夓偓鞐愳劀电� 須岇偓鞚� 欤检殧 鞛勳儊 頉勲炒氍检鞚� tegoprubart毳� 靻岅皽頃橂┌, 鞛リ赴 氚� 靹疙彫 鞚挫嫕 攵勳暭鞚� 鞛勳儊 臧滊皽, 韸鬼瀳 歆勴枆 欷戩澑 2靸� BESTOW 鞛勳儊鞁滍棙鞐� 欷戩爯鞚� 霊� 鞓堨爼鞛呺媹雼�.
R&D 雿办澊鞐惖鐢 Eledon鞚� 瓴届榿歆勱臣 氇呺 鞛埖鐢 旮瓣磤鞚� 鞚挫嫕 攵勳暭 鞝勲臧�霌れ澊 氚滍憸毳� 歆勴枆頃╇媹雼�. 氚滍憸 欤检牅电� 瓿犿槙 鞛リ赴 鞚挫嫕鞚� 氙胳订臁� 靾橃殧, 鞛勳儊 韽夑皜 旮办鞚� 氤�頇�, 攴鸽Μ瓿� 鞚挫瀽靹疙彫 鞚挫嫕 氚� 鞚挫 鞚挫嫕 攵勳暭鞚� 鞝勲灥鞝� 旮绊殞毳� 雼る０ 瓴冹瀰雼堧嫟. 頄夓偓电� 歆堨潣鞚戨嫷 靹胳厴鞙茧 毵堧毽悩氅�, 靸濎瓿� 鞗轨簮鞀ろ姼毳� 韱淀暣 鞁滌箔頃� 靾� 鞛堨姷雼堧嫟.
Eledon Pharmaceuticals (NASDAQ:ELDN) a annonc茅 qu鈥檈lle organisera une journ茅e R&D le 9 juillet 2025 脿 New York, 脿 partir de 8h30 ET. L鈥櫭﹙茅nement mettra en lumi猫re le principal candidat en investigation de la soci茅t茅, tegoprubart, en se concentrant sur son d茅veloppement clinique dans la transplantation d鈥檕rganes et de cellules, y compris l鈥檈ssai Phase 2 BESTOW en cours.
La journ茅e R&D comprendra des pr茅sentations de l鈥櫭﹒uipe de direction d鈥橢ledon ainsi que des experts renomm茅s en transplantation issus d鈥檌nstitutions prestigieuses. Les sujets aborderont les besoins non satisfaits dans la transplantation d鈥檕rganes solides, l鈥櫭﹙olution des crit猫res cliniques, ainsi que les opportunit茅s strat茅giques dans la transplantation de cellules des 卯lots et la x茅notransplantation. L鈥櫭﹙茅nement se terminera par une session de questions-r茅ponses et sera diffus茅 en direct par webcast.
Eledon Pharmaceuticals (NASDAQ:ELDN) gab bekannt, dass es am 9. Juli 2025 in New York City einen R&D-Tag veranstalten wird, der um 8:30 Uhr ET beginnt. Die Veranstaltung wird den f眉hrenden klinischen Kandidaten des Unternehmens, tegoprubart, vorstellen und sich auf dessen klinische Entwicklung im Bereich Organ- und Zelltransplantation konzentrieren, einschlie脽lich der laufenden Phase-2 BESTOW-Studie.
Der R&D-Tag beinhaltet Pr盲sentationen des Eledon-Managementteams sowie von f眉hrenden Transplantationsexperten renommierter Institutionen. Die Themen umfassen ungedeckte Bed眉rfnisse bei der Transplantation solider Organe, die Entwicklung klinischer Endpunkte sowie strategische Chancen bei Inselzelltransplantationen und Xenotransplantationen. Die Veranstaltung endet mit einer Fragerunde und wird per Live-Webcast 眉bertragen.
- None.
- None.
IRVINE, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (鈥淓ledon鈥�) (Nasdaq: ELDN) today announced that it will host an R&D Day in New York City on Wednesday, July 9, 2025 beginning at 8:30 am ET.
The event will feature members of Eledon鈥檚 executive team and the following leading experts in transplantation:
- Andrew Adams, M.D., Ph.D., Professor of Surgery and Chief Division of Transplantation, John S. Najarian Surgical Chair in Clinical Transplantation, Department of Surgery, University of Minnesota; Executive Medical Director, Solid Organ Transplant Service Line, M Health Fairview
- John D. Cleveland, M.D., Associate Professor of Clinical Surgery, Program Director, Congenital Cardiac Surgery Fellowship, Children鈥檚 Hospital Los Angeles, Department of Surgery, Keck School of Medicine
- William E. Fitzsimmons, Pharm.D., M.S., Adjunct Professor, University of Illinois Colleges of Medicine and Pharmacy; Executive Committee, Transplant Therapeutics Consortium
- Piotr Witkowski, M.D., Ph.D., Professor of Surgery and Director of the Pancreatic and Islet Transplant Program at UChicago Medicine
The R&D Day event will highlight Eledon鈥檚 lead investigational candidate, tegoprubart, with a focus on its clinical development in organ and cell transplantation, including the ongoing Phase 2 BESTOW trial. Additional sessions will address unmet needs in solid organ transplantation, the evolution of clinical endpoints such as iBox and eGFR, and the Company鈥檚 strategic opportunities in islet cell transplantation and xenotransplantation. The program will conclude with a live Q&A session featuring Eledon鈥檚 management team and invited key opinion leaders.
To register for the in-person event, please email: . A live webcast of the event and presentation materials will be available on the 鈥淓vents鈥� section of Eledon鈥檚 website at .
About聽Eledon Pharmaceuticals聽and tegoprubart
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company鈥檚 lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company鈥檚 website at .
Follow聽Eledon Pharmaceuticals聽on social media:聽;听
Investor Contact:
Stephen Jasper
Gilmartin Group
(858) 525 2047
Media Contact:
Jenna Urban
CG Life
(212) 253 8881
Source:聽Eledon Pharmaceuticals
FAQ
When and where is Eledon Pharmaceuticals (ELDN) hosting its R&D Day 2025?
What topics will be covered at Eledon's (ELDN) R&D Day 2025?
Who are the key speakers at Eledon's (ELDN) R&D Day 2025?
How can investors attend or access Eledon's (ELDN) R&D Day 2025?
